search
Back to results

The ELUTES Clinical Trial (ELUTES I)

Primary Purpose

Coronary Artery Disease

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
coronary stent
Sponsored by
Cook Group Incorporated
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Disease focused on measuring coronary artery, stent, drug eluting, patency, restenosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patient must be eligible to undergo planned treatment of a single de novo lesion in a native coronary artery. Patient must be an acceptable candidate for coronary artery bypass surgery. Patient or legal guardian must have signed informed consent. Patient agrees to return at one month for an office visit to assess cardiovascular status and at 6 months for an office visit to assess cardiovascular status and for a diagnostic angiogram. Exclusion Criteria: Patient must be less than 18 years old. Patient has history of bleeding diathesis or coagulopathy or will refuse blood transfusions. Patient is simultaneously participating in another investigative interventional cardiovascular device or drug study. Patient has known hypersensitivity or contraindication to aspirin, clopidogrel, or stainless steel, or a sensitivity to contrast dye. Women of child bearing potential. Patient has other medical condition that may cause non-compliance with the protocol, confound the results, or is associated with limited life expectancy. Patient has been diagnosed with a myocardial infarction within 72 hours prior to procedure.

Sites / Locations

  • Contact Sponsor

Outcomes

Primary Outcome Measures

Angiographic in-stent % diameter stenosis and late loss at follow up.

Secondary Outcome Measures

Major adverse events
Total lesion revascularization

Full Information

First Posted
September 12, 2005
Last Updated
January 30, 2012
Sponsor
Cook Group Incorporated
search

1. Study Identification

Unique Protocol Identification Number
NCT00225654
Brief Title
The ELUTES Clinical Trial
Acronym
ELUTES I
Official Title
The ELUTES Clinical Trial (European Evaluation of Paclitaxel Eluting Stent)
Study Type
Interventional

2. Study Status

Record Verification Date
January 2012
Overall Recruitment Status
Completed
Study Start Date
January 2000 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
November 2001 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Cook Group Incorporated

4. Oversight

5. Study Description

Brief Summary
ELUTES is a European multicenter, randomized, controlled, triple-blinded study designed to evaluate the ability of the Paclitaxel Eluting V-Flex Plus coronary stent to reduce restenosis in the coronary artery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
Keywords
coronary artery, stent, drug eluting, patency, restenosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
192 (false)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
coronary stent
Primary Outcome Measure Information:
Title
Angiographic in-stent % diameter stenosis and late loss at follow up.
Secondary Outcome Measure Information:
Title
Major adverse events
Title
Total lesion revascularization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient must be eligible to undergo planned treatment of a single de novo lesion in a native coronary artery. Patient must be an acceptable candidate for coronary artery bypass surgery. Patient or legal guardian must have signed informed consent. Patient agrees to return at one month for an office visit to assess cardiovascular status and at 6 months for an office visit to assess cardiovascular status and for a diagnostic angiogram. Exclusion Criteria: Patient must be less than 18 years old. Patient has history of bleeding diathesis or coagulopathy or will refuse blood transfusions. Patient is simultaneously participating in another investigative interventional cardiovascular device or drug study. Patient has known hypersensitivity or contraindication to aspirin, clopidogrel, or stainless steel, or a sensitivity to contrast dye. Women of child bearing potential. Patient has other medical condition that may cause non-compliance with the protocol, confound the results, or is associated with limited life expectancy. Patient has been diagnosed with a myocardial infarction within 72 hours prior to procedure.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anthony Gershlick, MD
Organizational Affiliation
Glenfield Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Contact Sponsor
City
Bloomington
State/Province
Indiana
Country
United States

12. IPD Sharing Statement

Learn more about this trial

The ELUTES Clinical Trial

We'll reach out to this number within 24 hrs